Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Increasing childhood vaccination coverage of the refugee and migrant population in Greece through the European programme PHILOS, April 2017 to April 2018.

Mellou K, Silvestros C, Saranti-Papasaranti E, Koustenis A, Pavlopoulou ID, Georgakopoulou T, Botsi C, Terzidis A.

Euro Surveill. 2019 Jul;24(27). doi: 10.2807/1560-7917.ES.2019.24.27.1800326.

2.

Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care.

Patel JD, Paz-Ares L, Zinner RG, Barlesi F, Koustenis AG, Obasaju CK.

Clin Lung Cancer. 2018 Nov;19(6):e823-e830. doi: 10.1016/j.cllc.2018.05.013. Epub 2018 May 26. Review.

PMID:
30369427
3.

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.

Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J.

Clin Cancer Res. 2017 Sep 1;23(17):5218-5224. doi: 10.1158/1078-0432.CCR-17-0754. Epub 2017 May 22. Erratum in: Clin Cancer Res. 2018 Nov 1;24(21):5485.

4.

Optical coherence tomography angiography: an overview of the technology and an assessment of applications for clinical research.

Koustenis A Jr, Harris A, Gross J, Januleviciene I, Shah A, Siesky B.

Br J Ophthalmol. 2017 Jan;101(1):16-20. doi: 10.1136/bjophthalmol-2016-309389. Epub 2016 Oct 4. Review.

PMID:
27707691
5.

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes E.

J Clin Oncol. 2016 Mar 20;34(9):953-62. doi: 10.1200/JCO.2015.64.8824. Epub 2016 Jan 25.

PMID:
26811519
7.

PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.

Zinner RG, Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, Modiano MR, Hrinczenko B, Nikolinakos PG, Liu J, Koustenis AG, Winfree KB, Melemed SA, Guba SC, Ortuzar WI, Desaiah D, Treat JA, Govindan R, Ross HJ.

J Thorac Oncol. 2015 Jan;10(1):134-42. doi: 10.1097/JTO.0000000000000366.

8.

Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer.

Choy H, Schwartzberg LS, Dakhil SR, Garon EB, Gerber DE, Choksi JK, Govindan R, Peng G, Koustenis A, Treat J, Obasaju C.

J Thorac Oncol. 2013 Oct;8(10):1308-16. doi: 10.1097/JTO.0b013e3182a02546.

9.

Pemetrexed in head and neck cancer: a systematic review.

Argiris A, Pennella E, Koustenis A, Hossain AM, Obasaju CK.

Oral Oncol. 2013 Jun;49(6):492-501. doi: 10.1016/j.oraloncology.2013.01.007. Epub 2013 Mar 7. Review.

PMID:
23466170
10.

Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study.

Urba S, van Herpen CM, Sahoo TP, Shin DM, Licitra L, Mezei K, Reuter C, Hitt R, Russo F, Chang SC, Hossain AM, Frimodt-Moller B, Koustenis A, Hong RL.

Cancer. 2012 Oct 1;118(19):4694-705. doi: 10.1002/cncr.27449. Epub 2012 Mar 20.

11.

Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy.

Urba S, Gatz J, Shen W, Hossain A, Winfree K, Koustenis A, Peterson P, Cohen EE.

Oral Oncol. 2012 Aug;48(8):723-9. doi: 10.1016/j.oraloncology.2012.02.016. Epub 2012 Mar 11.

PMID:
22414289
12.

Arabidopsis FHY3 specifically gates phytochrome signaling to the circadian clock.

Allen T, Koustenis A, Theodorou G, Somers DE, Kay SA, Whitelam GC, Devlin PF.

Plant Cell. 2006 Oct;18(10):2506-16. Epub 2006 Sep 29.

13.

Paclitaxel administration using portable infusion pumps.

Goldspiel BR, Kohler DR, Koustenis AG, Wilson WH, Tolcher AW, O'Shaughnessy JA, Wittes RE, Chabner BA.

J Clin Oncol. 1993 Nov;11(11):2287-8. No abstract available.

PMID:
7901343

Supplemental Content

Loading ...
Support Center